Previous Article | Next Article 
Journal of Virology, December 1999, p. 9843-9848, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Equine Herpesvirus 2 E1 Open Reading Frame
Encodes a Functional Chemokine Receptor
Grazia
Camarda,1
Gaia
Spinetti,1
Giovanni
Bernardini,1
Catherine
Mair,2
Nick
Davis-Poynter,2
Maurizio C.
Capogrossi,1 and
Monica
Napolitano1,*
Laboratorio di Patologia Vascolare, Istituto
Dermopatico dell'Immacolata-Istituto di Ricovero e Cura a Carattere
Scientifico, Rome, Italy,1 and
Laboratory of Virology, Animal Health Trust, Newmarket,
England2
Received 26 May 1999/Accepted 19 August 1999
 |
ABSTRACT |
Several herpesviruses contain open reading frames (ORFs) that
encode potential homologs of eucaryotic genes. Equine herpesvirus 2 (EHV-2) is a gammaherpesvirus related to other lymphotropic herpesviruses such as herpesvirus saimiri and Epstein-Barr virus. The
E1 ORF of EHV-2, a G protein-coupled receptor homolog, shows 31 to 47%
amino acid identity with known CC chemokine receptors. To investigate
whether E1 may encode a functional receptor, we cloned the E1 ORF and
expressed it in stably transfected cell lines. We report here the
identification of the CC chemokine eotaxin as a functional ligand for
the EHV-2 E1 receptor. Chemokines are likely to play a role in the
regulation of immune functions in equine hosts during EHV-2 infection
and, via interaction with E1, may affect viral replication and/or
escape from immune responses.
 |
INTRODUCTION |
Viruses often integrate in their own
genomes several cellular genes involved in the control of cell growth
and differentiation and/or in the regulation of immune functions. These
"pirated" genes may confer a replicative advantage to infecting
viruses by interfering with cellular functions and by subverting the
host immune system through molecular mimicry (2, 16, 22).
Herpesviruses and poxviruses frequently contain in their genome
host-derived genes homologous to immunoregulatory genes, such as
cytokines and cytokine receptors (4, 28), or to cell cycle
regulatory molecules such as bcl-2 and cyclins (4, 40, 49).
The gamma subfamily of herpesviruses generally replicates in
lymphoblastoid, epithelial, and fibroblastic cells, with the former
group of cells being the preferred site of latency. This subfamily is
further divided into the
1 genus (typified by the Epstein-Barr virus
[EBV]) and the
2 genus (e.g., herpesvirus saimiri [HVS] that
infects nonhuman primates and human herpesvirus 8 [HHV-8] associated
with Kaposi's sarcoma).
Over the past decade chemokines have been shown to play an important
role in inflammation, hematopoiesis, and angiogenesis, as well as in
atherosclerosis, tumor growth, and several other pathological
conditions (27, 34). Chemokines represent a family of
structurally related molecules whose conserved cysteine residues define
the two major subgroups of CXC and CC chemokines (7). Such
molecules interact with seven transmembrane-spanning receptors and
signal through the activation of heterotrimeric G proteins, thus
modulating several cellular functions (58).
Several herpesviruses have been found to encode chemokines and/or
chemokine receptor genes that may affect host immune responses or virus
tissue tropism and/or dissemination, thus contributing to viral
pathogenesis. A number of herpesvirus-encoded chemokine receptors have
been reported to be functional and able to bind known chemokines
(29, 38). Thus, HVS open reading frame (ORF) 74, also known
as ECRF3, is homologous to the CXCR2 receptor and binds and signals in
response to Gro
, NAP-2, and interleukin-8 (IL-8) (3).
Similarly, the cytomegalovirus (CMV) ORF US28, homologous to
CCR1, binds MIP-1
, MIP-1
, MCP-1, and RANTES and signals in
response to these ligands (20, 41). HHV-8 ORF 74 has been
extensively studied and shown to be a CXC chemokine receptor homolog
which, interestingly, while it exhibits constitutive signalling, may be
further activated by Gro
and IL-8 and inhibited by SDF-1, IP-10, and
Mig. This receptor is expressed in Kaposi's sarcoma lesions and
appears to act as a viral oncogene, inducing cell proliferation,
transformation, and tumor angiogenesis (6, 8, 21).
Equine herpesvirus 2 (EHV-2) is a lymphotropic gammaherpesvirus with a
high prevalence rate in horse populations (1). The complete
genome of EHV-2 (strain 86/67) has been determined, demonstrating that
it is more similar to
2 herpesviruses (e.g., HVS) than
1 herpesviruses (e.g., EBV) (52). While its role as a pathogen is still unclear, EHV-2 infection has been implicated in
immunosuppression in foals, in conjunctivitis, and in respiratory
inflammatory processes and poor racing performance (14, 30, 39,
47). EHV-2 has been isolated from peripheral blood mononuclear
cells of foals (39), from the respiratory tracts of animals
with clinical signs of disease, and from draining lymph nodes,
potentially representing the main viral reservoirs. Moreover, the virus
has been detected, at lower frequency, in both the peripheral and
central nervous systems, mostly in the trigeminal ganglion, a putative
site for EHV-2 latency (47). In addition, EHV-2 has been
proposed to act as a trans-activating factor, which may
either trigger or upregulate EHV-1 and EHV-4 expression from a latent
state (44, 59). EHV-2 contains 79 ORFs that encode 77 distinct molecules, several of which show striking homology to cellular
genes. These include an IL-10 homolog (E7); two proteins which interact
with apoptosis-signalling pathways, v-FLIP (E8) (55) and
v-CARMEN (E10) (54); and three putative G protein-coupled
receptors (GPCRs). EHV-2 ORF 74 is colinear and conserved (ca. 20%
homology) with the corresponding ORF of HVS (53). This ORF
is a characteristic feature of the
2 genus, being conserved in the
majority characterized to date (namely, HVS, EHV-2, HHV-8, and murine
gammaherpesvirus 68 (MHV-68) (57), with the exception of
alcephaline herpesvirus type 1 (18). ORF E6 is predicted to
encode a protein with seven transmembrane domains and other features
characteristic of GPCRs (53) and is homologous to the BILF1
ORF of EBV (16). The third GPCR homolog, ORF E1, is the only
identified diploid ORF within the EHV-2 genome, being encoded within
the terminal direct repeat elements.
The E1 ORF shows the highest degree of homology with cellular chemokine
receptors compared with other viral GPCRs and, among viral products, is
conserved most closely with the human CMV ORF US28 (53). Its
structural relatedness to this class of molecules suggests that it may
also share biological responses of classical chemokine receptors. We
therefore investigated whether E1 may be functionally active in
response to chemokines when expressed in eucaryotic cell lines and
found that this receptor responds to eotaxin in both calcium
mobilization and chemotaxis assays, suggesting a role of chemokines
during EHV-2 infection.
 |
MATERIALS AND METHODS |
Recombinant proteins.
Human I-309 was purchased from R&D
Systems (Minneapolis, Minn.) and human eotaxin, RANTES, MIP-1
,
MIP-1
, MCP-3, BCA-1, IP-10, and Mig were from PeproTech (London,
United Kingdom).
Molecular cloning of the E1 ORF into expression vectors.
Both nucleotide and protein sequences corresponding to known chemokine
receptors were used for comparative analysis of GenBank and other
databases to search for homologous receptors. Our bioinformatic screening of nonredundant databases identified the EHV-2 E1 ORF (accession number U20824) (53) as a putative chemokine receptor.
The entire E1 ORF was amplified from EHV-2 (strain 86/67) genomic DNA
(the kind gift of A. J. Davison, University of Glasgow) by PCR
with primers containing EcoRI restriction sites at their 5'
ends. The primer sequences were 5'-CAG AAT TCA TGG CAA CCA CTT CAG C-3'
(forward primer) and 5'-CAG AAT TCC ATG CTG GTG GTC CAT C-3' (backward
primer). After an initial denaturation step (5 min at 94°C), PCR was
performed with AmpliTaq DNA polymerase (Perkin-Elmer/Roche, Branchburg,
N.J.) for a total of 35 cycles (45 s at 94°C, 1 min at 60°C, and 1 min at 72°C), with a final extension at 72°C for 10 min. PCR
products were digested with EcoRI, gel purified, and
subcloned in the pcDNA3 expression vector (Invitrogen, Groningen, The
Netherlands) by standard procedures.
Creation of stably transfected cell lines.
293 human
embryonic kidney (HEK) cells were grown in Dulbecco modified Eagle
medium (DMEM) containing 10% fetal bovine serum (FBS) and 2 mM
glutamine; 300-19 murine pre-B cells were grown in complete medium
(RPMI, 10% FBS, glutamine, and 50 µM
-mercaptoethanol). Plasmids
were transfected into 293 cells by the calcium phosphate method as
previously described (11) and into 300-19 cells by electroporation. Briefly, 3 × 106 cells/400 µl were
mixed with 10 µg of plasmid DNA, incubated on ice for 10 min,
transferred to a 0.4-cm electroporation cuvette, and subjected to a
single pulse at 280 V and 960 µF (Gene Pulser II Apparatus; Bio-Rad
Laboratories, Hercules, Calif.). The electroporated cells were left on
ice for 15 min and resuspended in complete medium. At 48 h
posttransfection, with both methods, cells were placed under selection
in medium containing 1 mg of G418 (Life Technologies, Inc., Grand
Island, N.Y.) per ml for several weeks to generate stable transfectants.
RNA extraction and RT-PCR analysis.
Total RNA was extracted
from transfected cells by using the TRIzol Reagent (Life Technologies)
according to the manufacturer's instructions, digested with RNase-free
DNase (Promega, Madison, Wis.) for 1 h at 37°C, and purified.
First-strand cDNA was obtained by using Superscript II reverse
transcriptase (RT; Life Technologies) according to the manufacturer's
instruction. Briefly, 5 µg of total RNA was reverse transcribed in a
20-µl reaction mixture. Then, 1 µl of the cDNA template was PCR
amplified by using primer pairs and the cycling conditions described
above. The same amount of template was subjected to 25 cycles of PCR
amplification by using glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
primers as a control for normalization. The samples were then run on a 1.2% agarose gel in the presence of ethidium bromide and detected by
using a GelDoc 1000 apparatus (Bio-Rad Laboratories).
Intracellular [Ca2+] measurement.
300-19 cells
were loaded with Fluo4-AM (Molecular Probes, Inc., Eugene, Oreg.)
according to the manufacturer's instructions, with minor
modifications. Briefly, cells (5 × 106/ml) were
incubated in Hanks buffered saline solution without Ca2+
and Mg2+, supplemented with 10 mM HEPES (pH 7.4), and
containing 2.5 µM Fluo4-AM for 40 min at 37°C. Cells were
subsequently washed with Hanks solution and incubated at 37°C for 30 min in Hanks solution containing 10 mM HEPES, 5% FBS, and 2 mM
CaCl2 (HHF) to allow for complete fluorochrome
de-esterification. Cells where then washed twice in HHF and resuspended
in HHF at 2 × 106 cells/ml. Intracellular
[Ca2+] changes were evaluated by using a FACScan
cytofluorimeter (Becton-Dickinson, Mountain View, Calif.) equipped with
an argon laser (emission at 488 nm). After basal levels of fluorescence
were attained, cells were stimulated with chemokines (at 100 ng/ml),
and the fluorescence increase in the emission spectrum of Fluo4 (516 nm) was recorded every 10 s for 3 min. Intracellular
[Ca2+] levels were expressed as the fluorescence fold
increase, calculated by dividing the mean fluorescence intensities at
each time point of stimulation by the mean fluorescence intensity
recorded at time zero.
Chemotaxis assay.
The migration of 293 cells expressing the
E1 receptor was assessed as previously described (10, 46).
Briefly, cells were trypsinized, incubated in DMEM-10% FBS for 1 h at room temperature, washed in RPMI supplemented with 1% bovine
serum albumin-25 mM HEPES (migration medium [MM]), and placed in the
upper wells of a 48-well chemotaxis chamber (Neuro Probe, Inc., Cabin
John, Md.) at 0.5 × 106 cells/ml in triplicates in a
final volume of 50 µl. Chemokines were placed in the lower wells in a
27-µl volume of MM. Polyvinylpyrrolidone-free polycarbonate membranes
(12-µm pores) (Costar, Corning Inc., Corning, N.J.) were coated with
20 µg of mouse collagen type IV (Collaborative Biomedical Product;
Becton-Dickinson Labware, Bedford, Mass.) per ml for 2 h at
37°C. The chemotaxis assay was performed for 6 h at 37°C; the
filter was fixed and stained with a Diff-Quik Kit (DADE, Dudingen,
Switzerland), and the cells were counted at ×400 magnification in four
randomly selected fields. Migration indices were calculated by dividing
the average number of cells migrated in the presence of chemokines by
the number of cells migrated in migration medium alone.
RT-PCR analysis of E1 expression in EHV-2-infected cells.
Equine embryonic kidney cell monolayers (1.5 × 106
cells) were infected with approximately 0.01 PFU of EHV2 isolate 33839 (provided by the Animal Health Trust Diagnostic Services laboratory)
per cell and, after infection, maintained in minimal essential medium containing 5% FBS, glutamine, penicillin, and streptomycin. Cells were
harvested 5 days postinfection, and total RNA was extracted by using
the guanidine thiocyanate-based DNA/RNA Isolation Kit (USB, Cleveland,
Ohio) according to the manufacturer's instructions. Purification of
poly(A)+ RNA from 50 µl of total RNA (
250 µg of total
RNA) was performed by using Oligotex (Qiagen, GmbH) according to the
manufacturer's instructions. RT-PCR analysis of EHV-2 infected-cell
poly(A)+ RNA was performed as follows. First, 5 µl of
poly(A)+ RNA was mixed with 1 µl (40 U) of RNasin
(Promega) and 2 µl (200 ng) of Oligo(dT)15 Primer
(Promega), heated at 65°C for 5 min, and then quenched on ice for 2 min. Then, reverse transcription was performed by using M-MLV Reverse
Transcriptase (Promega), and the samples were incubated at 37°C for
60 min, 42°C for 60 min, and 95°C for 5 min. After reverse
transcription, the E1 ORF was amplified by PCR by using the forward
primer E1Ef (5'-TT CGA ATT CAC AGT AAA ATG GCA ACC AC-3') and the
reverse primer E1Er (5'-T TCG AAT TCA AAT GCG GGT GGG CCC CT-3') as
follows. A 5-µl portion of the above RT reaction mixture was
subjected to PCR amplification by using AmpliTaq DNA Polymerase
(Perkin-Elmer). After an initial denaturation step (94°C for 4 min),
PCR was performed for a total of 33 cycles (94°C for 30 s,
58°C for 1 min, and 72°C for 2 min), with a final extension at
72°C for 10 min. Amplified products were run on a 1.5% agarose in
1× TBE gel, and products were visualized by using ethidium bromide.
 |
RESULTS |
Cloning of EHV-2 E1 ORF and generation of cellular
transfectants.
In an effort to search for new members of the
chemokine receptor superfamily, we used selected amino acid sequences
corresponding either to complete ORFs or to conserved regions of these
receptors, in order to screen nucleotide and protein databases of both
expressed sequence tags (36) and nonredundant sequences.
This method allowed us to identify a number of molecules whose
predicted sequence matched GPCRs possibly belonging to the chemokine
receptor family. Among those we chose to characterize, the EHV-2 E1 ORF
was predicted to encode a 383-amino-acid (aa) seven-transmembrane
protein with significant homology with human CC-chemokine receptors,
specifically, CCR3 (47%), CCR1 (44%), CCR5 (40%), and CCR8 (35%)
(Table 1). In Fig.
1 the amino acid alignment of E1 and
human CCR3 by a CLUSTALW analysis is shown. Like most GPCRs, the E1
sequence shows an N-terminal extracellular domain, seven transmembrane
regions, three extracellular and intracellular loops, and a C-terminal
cytoplasmic tail. As for most chemokine receptors, the N-terminal
region is poorly conserved and is, in addition, considerably longer
compared to members of the chemokine receptor family. E1 shows three
potential N-linked glycosylation sites in its N-terminal region (aa 11 to 13, 22 to 24, and 42 to 44) and a protein kinase C (PKC)
phosphorylation site in its third intracellular loop (aa 270 to 272)
(Fig. 1).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 1.
Amino acid homology between EHV-2 E1 and human CCR3.
Alignment was done by using the CLUSTALW program. Two dots denote
identities, whereas single dots indicate conservative substitutions.
N-linked glycosylation (***) and PKC phosphorylation (ooo) sites
are marked. Gaps (dashes) were inserted from the program to obtain
maximum alignment.
|
|
To characterize the role of E1 as a chemokine receptor, we cloned the
entire E1 ORF, whose DNA was PCR amplified by using
oligonucleotides
based on the viral DNA sequence, into the pcDNA3
eucaryotic
expression vector and, after cell transfection, generated
cell lines
stably expressing the E1 protein. Both a lymphoid (300-19)
and an
epithelial (293/HEK) cell line were utilized. After G418
selection,
total RNA was extracted from stably transfected cells
and subjected to
RT-PCR amplification to verify E1 mRNA expression.
As depicted in Fig.
2 (upper panel), 300-19- and
293-transfected
cells showed the expression of a single band of 1,197 bp (lanes
2, 3, and 5) corresponding to an amplified message containing
the entire E1 ORF and flanking regions in comparison to the control
cells (lanes 1 and 4). PCR amplification of GAPDH, showed in the
lower
panel of Fig.
2, was used as a control for normalization.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 2.
RT-PCR analysis of E1 mRNA expression in E1-transfected
cells. (Upper panel) A single E1 mRNA transcript (1,197 bp) was
detected in two 300-19/E1 bulk transfectants (lane 2 and 3) and 293/E1
(lane 5) cells but not in 300-19/mock (lane 1) and 293/mock (lane 4)
cells. (Lower panel) GAPDH amplification (450 bp) was used for sample
normalization.
|
|
Functional characterization of transfected cells.
In order to
demonstrate that E1 may behave as a functional receptor and to identify
its potential agonists, we measured both calcium mobilization and
chemotaxis of E1- and mock-transfected cells in response to a panel of
CC and CXC chemokines. Both assays are widely utilized for the
characterization of chemokine receptors, since their ligands typically
induce such functional responses in target cells.
We first analyzed 300-19-transfected cells for calcium mobilization in
response to chemokines. As shown in Fig.
3, 300-19
E1 cells, loaded with Fluo4,
functionally responded to eotaxin
at a concentration of 100 ng/ml.
Eotaxin induced an increase in
the intracellular calcium concentration,
as measured by Fluo4
fluorescence intensity, after 30 s of
chemokine addition, which
reached a twofold increase over background
levels and then declined
progressively. By contrast, mock-transfected
cells did not show
any change in Fluo4 fluorescence upon eotaxin
addition (Fig.
3),
thus identifying eotaxin as a functional ligand for
EHV-2 E1.
Conversely, the CC chemokines RANTES, MIP-1

, MCP-3, and
I-309
and the CXC chemokines IP-10, Mig, and BCA-1 induced a barely
detectable increase of mean fluorescence intensities in both mock-
and
E1-transfected cells (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Intracellular calcium mobilization in E1-transfected
cells. Fluo4-loaded mock (closed circles)- and E1 (closed
squares)-transfected cells were analyzed by flow cytometry for calcium
mobilization after the addition of eotaxin (100 ng/ml). Results are
expressed as the fold increase of Fluo4 mean fluorescence intensities
compared to the emission at time zero. The data represent the average
(± the standard error of the mean [SEM]) of four independent
experiments.
|
|
We then measured the chemotactic responses of 293 cells to a panel of
chemokines in a 48-well microchamber assay. Such transfectants
were
chosen for their high level of E1 expression, as shown in
Fig.
2.
Eotaxin was tested in a wide range of concentrations on both mock- and
E1-transfected cells to confirm its activity as a chemoattractant.
As
shown in Fig.
4A, eotaxin induced a
potent chemotactic response
(migration index, 2 to 4) in
293/E1-transfected cells, with a
typical bell-shaped dose-response
curve and maximal activity of
agonist at a concentration of 100 to 300 ng/ml. These concentrations
did not elicit a chemotactic response in
mock-transfected cells
(Fig.
4A). Further, the CC chemokines RANTES,
MIP-1

, MIP-1

,
and MCP-3 did not induce a significant chemotactic
response in
either mock- or E1-transfected 293 cells (Fig.
4B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Chemotaxis of E1-transfected cells. (A) A range of
concentrations of eotaxin (from 10 to 500 ng/ml) was used in a 48-well
microchamber migration assay on mock (shaded columns)- and E1 (dashed
columns)-transfected cells. Migration indexes (± the SEM) are shown,
and the data represent the average of three to five independent
experiments. (B) Chemotaxis of mock (shaded columns)- and E1 (dashed
columns)-transfected cells in response to 100 ng of several CC
chemokines per ml. Migration indices (± the SEM) are shown for three
to five independent experiments.
|
|
In conclusion, while eotaxin induced both calcium mobilization and
chemotaxis in E1 transfectants, RANTES, MIP-1

, MIP-1

,
MCP-3,
I-309, BCA-1, IP-10, and Mig did not elicit functional
activation of E1
transfectants in either calcium or chemotaxis
assays.
RT-PCR analysis of E1 expression in EHV-2-infected cells.
In
order to confirm that the E1 ORF is transcribed in EHV-2-infected
cells, we determined whether E1 mRNA is expressed by RT-PCR analysis.
Primary equine embryonic kidney cells were infected with a field
isolate of EHV-2 and harvested 5 days postinfection (after the
development of significant cytopathic effect). Cell lysates were
processed for the preparation of poly(A)+ RNA and analyzed
by RT-PCR by using oligo(dT) to prime cDNA synthesis, followed by PCR
with E1 specific primers. As shown in Fig.
5, E1-specific mRNA was detected in
EHV-2-infected (lane 4) but not in mock-infected (lane 5) cells. Thus,
mRNA of the correct orientation for expression of E1 is transcribed in
EHV-2-infected equine cells.

View larger version (95K):
[in this window]
[in a new window]
|
FIG. 5.
RT-PCR detection of E1 mRNA in EHV-2-infected cells.
Virus-infected cells were probed for the expression of mRNA encoding E1
by RT-PCR with oligo(dT)-primed cDNA synthesis, followed by PCR
amplification with E1-specific primers. Lanes: 1, kilobase ladder; 2, PCR of EHV-2 DNA template; 3, RT-PCR of poly(A)+ RNA from
EHV-2-infected cells in the absence of RT treatment; 4, RT-PCR of
poly(A)+ RNA from EHV-2-infected cells in the presence of
RT treatment; 5, RT-PCR of total RNA from uninfected cells.
|
|
 |
DISCUSSION |
EHV-2 has been found to encode ORFs with significant homology to
cellular immunomodulatory proteins, similarly to other
gammaherpesviruses. These include an IL-10 homolog (E7) that may be
involved in the suppression of antiviral immune functions and three
GPCR homologs (ORFs E1, E6, and 74) that potentially interact with
cellular chemokines (53). To date, however, there has been
no direct demonstration of activity for the proteins encoded by these
ORFs or of their gene expression during infection.
E1 has been identified as a putative CC chemokine receptor that is
highly related to CCR3 (47% identities) and other chemokine receptors.
The high degree of homology shown by E1 with cellular receptors
belonging to this family is striking compared with other viral GPCRs,
which are usually more distantly related to eucaryotic counterparts,
and suggests that this ORF has been acquired relatively recently. The
location of E1 in the viral genome, namely, within the terminal repeat
elements, distal to the "core" blocks of genes conserved with other
gammaherpesviruses, further supports this hypothesis.
Our studies show that the chemokine receptor-like E1 ORF encodes a
functional receptor, since we identified the CC chemokine eotaxin as a
ligand able to induce both calcium mobilization and chemotaxis in
cellular transfectants overexpressing the E1 protein, whereas a number
of other chemokines, either CC or CXC, were ineffective. Furthermore,
we have demonstrated that mRNA encoding E1 is expressed upon EHV-2
infection of equine cells in tissue culture.
A certain degree of functional redundancy may be hypothesized for
chemokine receptors (7), since they often share common ligands and biological functions (i.e., chemotaxis) and are distributed on similar leukocyte subpopulations. However, there are several examples of discrete roles attributed either to selected ligands (15, 23) or to chemokine receptors (13, 25, 51,
60) by the use of genetically modified mice, as well as the
demonstration of discrete ligand and receptor expression on leukocyte
populations in pathophysiological states (34). Eotaxin
represents a typical example of a "specialized" function, playing
an important role during allergic reactions and parasitic infections;
this chemokine is produced locally by inflamed tissues and is a potent
activator of eosinophils and basophils (26, 31, 43).
Moreover, eotaxin-deficient mice show an impaired allergen-induced
eosinophil infiltration in the lungs (48), and eotaxin has a
role in the growth of granulocytic progenitors and in the
differentiation of embryonic mast cell progenitors (45).
Eotaxin is a selective ligand for CCR3, while its other agonists,
RANTES, eotaxin-2, and MCP-2, -3, and -4 (19, 42, 56), are
also able to bind other chemokine receptors. CCR3 is mostly expressed
by eosinophils, basophils (42, 56), and Th2 lymphocytes (50) that are recruited at sites of allergic inflammation;
therefore, this ligand-receptor pair is crucially involved in the
generation of allergic reactions, antihelminth responses and,
potentially, the modulation of responses after other infections.
Examples of virus-host interactions have been described for several
classes of viruses and, in particular, several viral ORFs encode for
chemokines and chemokine receptors. This suggests strongly that these
molecules may possess important regulatory functions for viral escape
from, or interaction with, immune responses (2, 16, 22).
Human CMV (37) encodes four potential chemokine receptors:
UL33, UL78, US27, and US28. US28 is a functionally active molecule (20, 41), and it has been recently shown that its expression may alter chemokine levels in the supernatant of infected cells, possibly by a sequestration mechanism (12), potentially
affecting immune responses, cellular proliferation and, ultimately, the course of viral infection. UL33, conserved in murine and rat CMV (M33
and R33, respectively) encodes a chemokine receptor-like molecule that,
when mutated, does not affect viral replication in tissue culture but
is important for murine and rat CMV replication in salivary glands,
suggesting a potential role of this receptor in viral tropism (9,
17, 35).
Poxviruses provide additional evidence for the importance of chemokines
in controlling viral spread through the identification of distinct
viral mechanisms for interfering with chemokine function. Examples are
represented by a chemokine homolog encoded by molluscum contagiosum
virus (MC148R), functional as an antagonist for several chemokines
(32), and myxoma virus MT-7, a low-affinity
chemokine-binding protein that interacts with the heparin-binding
domain of chemokines, thereby potentially disrupting their normal
association with the extracellular matrix (33). Similarly,
the vCKBP protein of the T1/35K family, expressed by myxoma, vaccinia,
cowpox and camelpox viruses, binds to CXC, C, and CC chemokines,
thereby blocking their interaction with chemokine receptors (5,
24). Functions of vCKBP have been demonstrated, namely, the
inhibition of eotaxin-induced eosinophil infiltration in an in vivo
model of allergic inflammation and the inhibition of leukocyte
recruitment to foci of rabbitpox virus infection (24).
Our demonstration of a functional activity of the EHV-2 E1 ORF
indicates that this virally encoded chemokine receptor may play a role
in the subversion of immune functions during EHV-2 infection. Possible
functions include the sequestration of cellular chemokines at sites of
infection, the modulation of virus replication in the presence of
secreted chemokines, or the altered trafficking of virus-infected cells
in response to chemokine gradients. Elucidation of the biological
significance of E1 during virus infection may be achieved through
characterization of mutant EHV-2 viruses with the E1 ORF deleted,
thereby determining the influence of E1 upon virus replication and
tissue tropism in vitro and in vivo.
 |
ACKNOWLEDGMENTS |
We are grateful to A. J. Davison for kindly providing the
EHV-2 viral DNA and Helen Farrell for critically reviewing the manuscript.
This work was partially supported by funding from the ISS-National AIDS
Program and the CNR-Biotechnology Program to M.N. N.D.-P. is a
Tetra Laval Senior Fellow in Virology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratorio di
Patologia Vascolare, Istituto Dermopatico dell'Immacolata-IRCCS, Via Monti di Creta 104, 00167 Rome, Italy. Phone: 39-06-66462431. Fax:
39-06-66462430. E-mail: m.napolitano{at}idi.it.
 |
REFERENCES |
| 1.
|
Agius, C. T., and M. J. Studdert.
1994.
Equine herpesviruses 2 and 5: comparisons with other members of the subfamily gammaherpesvirinae.
Adv. Virus Res.
44:357-379[Medline].
|
| 2.
|
Ahuja, S. K.,
J. L. Gao, and P. M. Murphy.
1994.
Chemokine receptors and molecular mimicry.
Immunol. Today
15:281-287[Medline].
|
| 3.
|
Ahuja, S. K., and P. M. Murphy.
1993.
Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri.
J. Biol. Chem.
268:20691-20694[Abstract/Free Full Text].
|
| 4.
|
Albrecht, J. C.,
J. Nicholas,
D. Biller,
K. R. Cameron,
B. Biesinger,
C. Newman,
S. Wittmann,
M. A. Craxton,
H. Coleman,
B. Fleckenstein, and K. W. Honess.
1992.
Primary structure of the herpesvirus saimiri genome.
J. Virol.
66:5047-5058[Abstract/Free Full Text].
|
| 5.
|
Alcamì, A.,
J. A. Symons,
P. D. Collins,
T. J. Williams, and G. L. Smith.
1998.
Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus.
J. Immunol.
160:624-633[Abstract/Free Full Text].
|
| 6.
|
Arvanitakis, L.,
E. Geras-Raaka,
A. Varma,
M. C. Gershengorn, and E. Cesarman.
1997.
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation.
Nature
385:347-350[Medline].
|
| 7.
|
Baggiolini, M.,
B. Dewald, and B. Moser.
1997.
Human chemokines: an update.
Annu. Rev. Immunol.
15:675-705[Medline].
|
| 8.
|
Bais, C.,
B. Santomasso,
O. Coso,
L. Arvanitakis,
E. Geras-Raaka,
J. S. Gutkind,
A. S. Asch,
E. Cesarman,
M. C. Gershengorn, and E. A. Mesri.
1998.
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.
Nature
391:86-89[Medline].
|
| 9.
|
Beisser, P. S.,
C. Vink,
J. G. Van Dam,
G. Grauls,
S. J. Vanherle, and C. A. Bruggeman.
1998.
The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection.
J. Virol.
72:2352-2363[Abstract/Free Full Text].
|
| 10.
|
Ben-Baruch, A.,
L. Xu,
P. R. Young,
K. Bengali,
J. J. Oppenheim, and J. M. Wang.
1995.
Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 /Rantes, is also a functional receptor for MCP3.
J. Biol. Chem.
270:22123-22128[Abstract/Free Full Text].
|
| 11.
|
Bernardini, G.,
J. Hedrick,
S. Sozzani,
W. Luini,
G. Spinetti,
M. Weiss,
S. Menon,
A. Zlotnik,
A. Mantovani,
A. Santoni, and M. Napolitano.
1998.
Identification of the CC chemokines TARC and macrophage inflammatory protein-1 as novel functional ligands for the CCR8 receptor.
Eur. J. Immunol.
28:582-588[Medline].
|
| 12.
|
Bodaghi, B.,
T. R. Jones,
D. Zipeto,
C. Vita,
L. Sun,
L. Laurent,
F. Arenzana-Seisdedos,
J. L. Virelizier, and S. Michelson.
1998.
Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells.
J. Exp. Med.
188:855-866[Abstract/Free Full Text].
|
| 13.
|
Boring, L.,
J. Gosling,
M. Cleary, and I. F. Charo.
1998.
Decreased lesion formation in CCR2 / mice reveals a role for chemokines in the initiation of atherosclerosis.
Nature
394:894-897[Medline].
|
| 14.
|
Collinson, P. N.,
J. L. O'Rielly,
N. Ficorilli, and M. J. Studdert.
1994.
Isolation of equine herpesvirus type 2 (equine gammaherpesvirus 2) from foals with keratoconjunctivitis.
J. Am. Vet. Med. Assoc.
205:329-331[Medline].
|
| 15.
|
Cook, D. N.,
M. A. Beck,
T. M. Coffman,
S. L. Kirby,
J. F. Sheridan,
I. B. Pragnell, and O. Smithies.
1995.
Requirement of MIP-1 for inflammatory response to viral infection.
Science
269:1583-1585[Abstract/Free Full Text].
|
| 16.
|
Davis-Poynter, N. J., and H. E. Farrell.
1996.
Masters of deception: a review of herpesvirus immune evasion strategies.
Immunol. Cell. Biol.
74:513-522[Medline].
|
| 17.
|
Davis-Poynter, N. J.,
D. M. Lynch,
H. Vally,
G. R. Shellam,
W. D. Rawlinson,
B. G. Barrell, and H. E. Farrell.
1997.
Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus.
J. Virol.
71:1521-1529[Abstract].
|
| 18.
|
Ensser, A.,
R. Pflanz, and B. Fleckenstein.
1997.
Primary structure of the alcelaphine herpesvirus 1 genome.
J. Virol.
71:6517-6525[Abstract].
|
| 19.
|
Forssmann, U.,
M. Uguccioni,
P. Loetscher,
C. A. Dahinden,
H. Langen,
M. Thelen, and M. Baggiolini.
1997.
Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.
J. Exp. Med.
185:2171-2176[Abstract/Free Full Text].
|
| 20.
|
Gao, J. L., and P. M. Murphy.
1994.
Human cytomegalovirus open reading frame US28 encodes a functional chemokine receptor.
J. Biol. Chem.
269:28539-28542[Abstract/Free Full Text].
|
| 21.
|
Geras-Raaka, E.,
L. Arvanitakis,
C. Bais,
E. Cesarman,
E. A. Mesri, and M. C. Gershengorn.
1998.
Inhibition of constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in culture.
J. Exp. Med.
187:801-806[Abstract/Free Full Text].
|
| 22.
|
Gooding, L. R.
1992.
Virus proteins that counteract host immune defenses.
Cell
71:5-7[Medline].
|
| 23.
|
Graham, G. J.,
E. G. Wright,
R. Hewick,
S. D. Wolpe,
N. M. Wilkie,
D. Donaldson,
S. Lorimore, and I. B. Pragnell.
1990.
Identification and characterization of an inhibitor of haemopoietic stem cell proliferation.
Nature
344:442-444[Medline].
|
| 24.
|
Graham, K. A.,
A. S. Lalani,
J. L. Macen,
T. L. Ness,
M. Barry,
L. Y. Liu,
A. Lucas,
I. Clark-Lewis,
R. W. Moyer, and G. McFadden.
1997.
The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues.
Virology
229:12-24[Medline].
|
| 25.
|
Gu, L.,
Y. Okada,
S. K. Clinton,
C. Gerard,
G. K. Sukhova,
P. Libby, and B. J. Rollins.
1998.
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.
Mol. Cell
2:275-281[Medline].
|
| 26.
|
Heath, H.,
S. Qin,
P. Rao,
L. Wu,
G. LaRosa,
N. Kassam,
P. D. Ponath, and C. R. Mackay.
1997.
Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.
J. Clin. Investig.
99:178-184[Medline].
|
| 27.
|
Howard, O. M.,
A. Ben-Baruch, and J. J. Oppenheim.
1996.
Chemokines: progress toward identifying molecular targets for therapeutic agents.
Trends Biotechnol.
14:46-51[Medline].
|
| 28.
|
Hsu, D. H.,
R. de Waal Malefyt,
D. F. Fiorentino,
M. N. Dang,
P. Vieira,
J. de Vries,
H. Spits,
T. R. Mosmann, and K. W. Moore.
1990.
Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1.
Science
250:830-832[Abstract/Free Full Text].
|
| 29.
|
Isegawa, Y.,
Z. Ping,
K. Nakano,
N. Sugimoto, and K. Yamanishi.
1998.
Human herpesvirus 6 open reading frame U12 encodes a functional -chemokine receptor.
J. Virol.
72:6104-6112[Abstract/Free Full Text].
|
| 30.
|
Jensen-Waern, M.,
S. G. Persson,
A. Nordengrahn,
M. Merz, and C. Fossum.
1998.
Temporary suppression of cell-mediated immunity in standardbred horses with decreased athletic capacity.
Acta Vet. Scand.
39:25-33[Medline].
|
| 31.
|
Jose, P. J.,
D. A. Griffiths-Johnson,
P. D. Collins,
D. T. Walsh,
R. Moqbel,
N. F. Totty,
O. Truong,
J. J. Hsuan, and T. J. Williams.
1994.
Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.
J. Exp. Med.
179:881-887[Abstract/Free Full Text].
|
| 32.
|
Krathwohl, M. D.,
R. Hromas,
D. R. Brown,
H. E. Broxmeyer, and K. H. Fife.
1997.
Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2.
Proc. Natl. Acad. Sci. USA
94:9875-9880[Abstract/Free Full Text].
|
| 33.
|
Lalani, A. S.,
K. Graham,
K. Mossman,
K. Rajarathnam,
I. Clark-Lewis,
D. Kelvin, and G. McFadden.
1997.
The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines.
J. Virol.
71:4356-4363[Abstract].
|
| 34.
|
Luster, A. D.
1998.
Chemokines chemotactic cytokines that mediate inflammation.
N. Engl. J. Med.
338:436-445[Free Full Text].
|
| 35.
|
Margulies, B. J.,
H. Browne, and W. Gibson.
1996.
Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles.
Virology
225:111-125[Medline].
|
| 36.
|
Marra, M. A.,
L. Hillier, and R. H. Waterston.
1998.
Expressed sequence tags ESTablishing bridges between genomes.
Trends Genet.
14:4-7[Medline].
|
| 37.
|
Mocarski, E. S.
1996.
Cytomegaloviruses and their replication, p. 2447-2487.
In
B. N. Fields, et al. (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa
|
| 38.
|
Murphy, P. M.
1997.
Pirated genes in Kaposi's sarcoma.
Nature
385:296-299[Medline].
|
| 39.
|
Murray, M. J.,
E. S. Eichorn,
E. J. Dubovi,
W. B. Ley, and D. M. Cavey.
1996.
Equine herpesvirus type 2: prevalence and seroepidemiology in foals.
Equine Vet. J.
28:432-436[Medline].
|
| 40.
|
Nava, V. E.,
E. H. Cheng,
M. Veliuona,
S. Zou,
R. J. Clem,
M. L. Mayer, and J. M. Hardwick.
1997.
Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogene.
J. Virol.
71:4118-4122[Abstract].
|
| 41.
|
Neote, K.,
D. DiGregorio,
J. Y. Mak,
R. Horuk, and T. J. Schall.
1993.
Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.
Cell
72:415-425[Medline].
|
| 42.
|
Ponath, P. D.,
S. Qin,
T. W. Post,
J. Wang,
L. Wu,
N. P. Gerard,
W. Newman,
C. Gerard, and C. R. Mackay.
1996.
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.
J. Exp. Med.
183:2437-2448[Abstract/Free Full Text].
|
| 43.
|
Ponath, P. D.,
S. Qin,
D. J. Ringler,
I. Clark-Lewis,
J. Wang,
N. Kassam,
H. Smith,
X. Shi,
J. A. Gonzalo,
W. Newman,
J. C. Gutierrez-Ramos, and C. R. Mackay.
1996.
Cloning of the human eosinophil chemoattractant, eotaxin: expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils.
J. Clin. Investig.
97:604-612[Medline].
|
| 44.
|
Purewal, A. S.,
A. V. Smallwood,
A. Kaushal,
D. Adegboye, and N. Edington.
1992.
Identification and control of the cis-acting elements of the immediate early gene of equid herpesvirus type 1.
J. Gen. Virol.
73:513-519[Abstract/Free Full Text].
|
| 45.
|
Quackenbush, E. J.,
B. K. Wershil,
V. Aguirre, and J. C. Gutierrez-Ramos.
1998.
Eotaxin modulates myelopoiesis and mast cell development from embryonic hematopoietic progenitors.
Blood
92:1887-1897[Abstract/Free Full Text].
|
| 46.
|
Richmond, A.,
S. Mueller,
J. R. White, and W. Schraw.
1997.
C-X-C chemokine receptor desensitization mediated through ligand-enhanced receptor phosphorylation on serine residues.
Methods Enzymol.
288:3-15[Medline].
|
| 47.
|
Rizvi, S. M.,
J. D. Slater,
U. Wolfinger,
K. Borchers,
H. J. Field, and A. J. Slade.
1997.
Detection and distribution of equine herpesvirus 2 DNA in the central and peripheral nervous systems of ponies.
J. Gen. Virol.
78:1115-1118[Abstract].
|
| 48.
|
Rothenberg, M. E.,
J. A. MacLean,
E. Pearlman,
A. D. Luster, and P. Leder.
1997.
Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia.
J. Exp. Med.
185:785-790[Abstract/Free Full Text].
|
| 49.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 50.
|
Sallusto, F.,
C. R. Mackay, and A. Lanzavecchia.
1997.
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.
Science
277:2005-2007[Abstract/Free Full Text].
|
| 51.
|
Tachibana, K.,
S. Hirota,
H. Iizasa,
H. Yoshida,
K. Kawabata,
Y. Kataoka,
Y. Kitamura,
K. Matsushima,
N. Yoshida,
S. Nishikawa,
T. Kishimoto, and T. Nagasawa.
1998.
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature
393:591-594[Medline].
|
| 52.
|
Telford, E. A. R.,
M. J. Studdert,
C. T. Agius,
M. S. Watson,
H. C. Aird, and A. J. Davison.
1993.
Equine herpesviruses 2 and 5 are -herpesviruses.
Virology
195:492-499[Medline].
|
| 53.
|
Telford, E. A. R.,
M. S. Watson,
H. C. Aird,
J. Perry, and A. J. Davison.
1995.
The DNA sequence of equine herpesvirus 2.
J. Mol. Biol.
249:520-528[Medline].
|
| 54.
|
Thome, M.,
F. Martinon,
K. Hofmann,
V. Rubio,
V. Steiner,
P. Schneider,
C. Mattmann, and J. Tschopp.
1999.
Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF- B transcription factor and c-Jun N-terminal kinase.
J. Biol. Chem.
274:9962-9968[Abstract/Free Full Text].
|
| 55.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Fickenscher,
E. Meinl,
F. Neipel,
C. Mattmann,
K. Burns,
J. L. Bodmer,
M. Schroter,
C. Scaffidi,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[Medline].
|
| 56.
|
Uguccioni, M.,
C. R. Mackay,
B. Ochensberger,
P. Loetscher,
S. Rhis,
G. J. LaRosa,
P. Rao,
P. D. Ponath,
M. Baggiolini, and C. A. Dahinden.
1997.
High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.
J. Clin. Investig.
100:1137-1143[Medline].
|
| 57.
|
Virgin, H. W., IV,
P. Latreille,
P. Wamsley,
K. Hallsworth,
K. E. Weck,
A. J. Dal Canto, and S. H. Speck.
1997.
Complete sequence and genomic analysis of murine gammaherpesvirus 68.
J. Virol.
71:5894-5904[Abstract].
|
| 58.
|
Ward, S. G.,
K. Bacon, and J. Westwick.
1998.
Chemokines and T lymphocytes: more than an attraction.
Immunity
9:1-11[Medline].
|
| 59.
|
Welch, H. M.,
C. G. Bridges,
A. M. Lyon,
L. Griffiths, and N. Edington.
1992.
Latent equid herpesviruses 1 and 4: detection and distinction using the polymerase chain reaction and co-cultivation from lymphoid tissues.
J. Gen. Virol.
73:261-268[Abstract/Free Full Text].
|
| 60.
|
Zou, Y. R.,
A. H. Kottmann,
M. Kuroda,
I. Taniuchi, and D. R. Littman.
1998.
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.
Nature
393:595-599[Medline].
|
Journal of Virology, December 1999, p. 9843-9848, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sharp, E. L., Farrell, H. E., Borchers, K., Holmes, E. C., Davis-Poynter, N. J.
(2007). Sequence analysis of the equid herpesvirus 2 chemokine receptor homologues E1, ORF74 and E6 demonstrates high sequence divergence between field isolates. J. Gen. Virol.
88: 2450-2462
[Abstract]
[Full Text]
-
Nicholas, J
(2000). Evolutionary aspects of oncogenic herpesviruses. Mol. Pathol.
53: 222-237
[Abstract]
[Full Text]
-
Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., Power, C. A.
(2000). International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev.
52: 145-176
[Abstract]
[Full Text]